MARKET
IPO

ATTO

Attovia Therapeutics
ATTO
NASDAQ
Upcoming IPOs
Expected Listing Date: 2026-08-05
P/E
P/S
P/B
MARKET CAP
INDUSTRY
-1.10~-0.97
-
-
577.94M~654.99M
Biotechnology & Medical Research
2026-07-14
Public Filing
View Prospectus
Pending
Offering
Price Range: 15.00~17.00
Shares to be Issued: 12.50M
2026-08-04
Offering End Date
Offering Price: Pending
Post IPO Outstanding: 38.53M
2026-08-05
Listed
Braveheart Bio, Attovia seek $275M and $182M in U.S. IPOs
Seeking Alpha · 14h ago
About ATTO
Attovia Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing biotherapeutics for immune-mediated diseases with high unmet need. Its lead pipeline candidates target commercially validated pathways and are designed through its ATTOBODY biologics platform to deliver improved treatments relative to the standards of care. Its ATTOBODY platform uses an evolution-driven, high-throughput process which allows for discovery and creation of a high diversity of potential product candidates. It is developing a pipeline of novel biotherapeutics for the treatment of immune-mediated diseases. Its first two product candidates for its immune-dermatology franchise, ATTO-1310 and ATTO-2306, have the potential to treat patients suffering from pruritic and lesional diseases. Its third program, ATTO-1091, broadens its reach to other inflammatory diseases, such as IBD, a therapeutic area with substantial unmet need. ATTO-1310 is an ATTOBODY-based therapeutic targeting interleukin-31.

Webull offers Attovia Therapeutics stock information, including NASDAQ: ATTO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ATTO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ATTO stock methods without spending real money on the virtual paper trading platform.